A detailed history of Savant Capital, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Savant Capital, LLC holds 82,827 shares of BMRN stock, worth $4.53 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
82,827
Previous 53,653 54.38%
Holding current value
$4.53 Million
Previous $2.95 Million 52.09%
% of portfolio
0.03%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 04, 2025

BUY
$52.62 - $61.93 $1.54 Million - $1.81 Million
29,174 Added 54.38%
82,827 $4.49 Million
Q2 2025

Aug 06, 2025

SELL
$54.08 - $68.32 $1 Million - $1.26 Million
-18,503 Reduced 25.64%
53,653 $2.95 Million
Q1 2025

May 08, 2025

BUY
$61.25 - $72.83 $2.65 Million - $3.15 Million
43,220 Added 149.36%
72,156 $5.1 Million
Q4 2024

Jan 28, 2025

BUY
$61.93 - $70.49 $924,614 - $1.05 Million
14,930 Added 106.6%
28,936 $1.9 Million
Q3 2024

Nov 04, 2024

BUY
$69.02 - $93.84 $966,694 - $1.31 Million
14,006 New
14,006 $984,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $10.2B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Savant Capital, LLC Portfolio

Follow Savant Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Savant Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Savant Capital, LLC with notifications on news.